OncoMatch/Clinical Trials/NCT06246110
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Is NCT06246110 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for nsclc.
Treatment: EIK1001 · Pembrolizumab · Paclitaxel · Pemetrexed · Carboplatin — This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR wild-type
documentation of absence of tumor activating mutations/fusions that are approved for first line therapy
Required: ALK wild-type
documentation of absence of tumor activating mutations/fusions that are approved for first line therapy
Required: ROS1 wild-type
documentation of absence of tumor activating mutations/fusions that are approved for first line therapy
Required: BRAF wild-type
documentation of absence of tumor activating mutations/fusions that are approved for first line therapy
Required: MET wild-type
documentation of absence of tumor activating mutations/fusions that are approved for first line therapy
Required: RET wild-type
documentation of absence of tumor activating mutations/fusions that are approved for first line therapy
Required: NTRK1 wild-type
documentation of absence of tumor activating mutations/fusions that are approved for first line therapy
Required: NTRK2 wild-type
documentation of absence of tumor activating mutations/fusions that are approved for first line therapy
Required: NTRK3 wild-type
documentation of absence of tumor activating mutations/fusions that are approved for first line therapy
Required: KRAS wild-type
documentation of absence of tumor activating mutations/fusions that are approved for first line therapy
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
have not received prior systemic treatment for advanced/metastatic NSCLC
Cannot have received: investigational therapy
Exception: if received within 4 weeks or 5 half-lives (whichever is shorter) of administration of EIK1001
is currently participating in or has participated in a study of an investigational agent and received investigational therapy within 4 weeks or 5 half-lives (whichever is shorter) of administration of EIK1001
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
have adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Southern Cancer Care · Daphne, Alabama
- Ironwood Cancer and Research Center · Chandler, Arizona
- California Cancer Care Associates for Research & Excellence · Fresno, California
- California Research Institute · Los Angeles, California
- University of Southern California, Norris Comprehensive Cancer Center · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify